Background. Combination antimalarial therapy is advocated to improve treatment efficacy and limit selection of drug-resistant parasites. We compared the efficacies of 3 combination regimens in Bobo-Dioulasso, Burkina Faso: amodiaquine plus sulfadoxinepyrimethamine, which was recently shown to be highly efficacious at this site; artemether-lumefantrine, the new national firstline antimalarial regimen; and dihydroartemisinin-piperaquine (DP), a newer regimen.
ACT in Africa is artemether-lumefantrine, which has recently been selected as first-line therapy by 20 countries [4] [5] [6] [7] and was chosen for this purpose by Burkina Faso in 2005 [8] . However, as is the case in many countries, routine provision of artemether-lumefantrine for uncomplicated malaria has not been widely implemented in Burkina Faso because of limitations on resources and drug availability.
In West Africa, where resistance to older regimens is less common than it is in other areas, the combination of amodiaquine plus sulfadoxine-pyrimethamine (AQSP) has shown excellent antimalarial efficacy [9] [10] [11] . AQSP is inexpensive and provides extended drug levels after treatment, offering a potential advantage over some ACT regimens. Indeed, when compared with artemether-lumefantrine therapy in Burkina Faso, treatment with AQSP provided similarly strong activity against infecting parasites but better protection against new infections, such that the rate of recurrent malaria within 28 days after therapy was significantly lower with the AQSP regimen [7] .
Treatment with dihydroartemisinin-piperaquine, a newer ACT, has shown excellent antimalarial efficacy in available trials [12] [13] [14] [15] [16] [17] [18] and appears to offer advantages over artemether-lumefantrine, including simpler dosing and the longer half-life of piperaquine, compared with that of lumefantrine. We compared the antimalarial efficacy and safety of AQSP, artemetherlumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Bobo-Dioulasso, Burkina Faso.
PATIENTS AND METHODS
Study site. Subjects were recruited from 3 government health dispensaries in Bobo-Dioulasso, in western Burkina Faso. In this region, malaria is holoendemic, with transmission principally occurring during the rainy season (May-October). The study was approved by the institutional review boards of the Institut de Recherche en Sciences de la Santé/Centre Muraz (Bobo-Dioulasso, Burkina Faso) and the University of California, San Francisco.
Patients. Consecutive patients with fever or a history of recent fever were referred for a Giemsa-stained thick blood smear, and those with a positive smear result were assessed by study clinicians for the following inclusion criteria: age у6 months; weight у5 kg; fever (axillary temperature у37.5ЊC) or fever symptoms within the previous 24 h; absence of history of serious adverse effects related to study medications, including sulfa allergy; no evidence of a concomitant febrile illness; provision of informed consent by the patient or parents or guardians, as well as the ability to participate in a 42-day follow-up; no history of treatment with any antimalarial drug other than chloroquine in the previous 2 weeks; no danger signs or evidence of severe malaria [19] ; P. falciparum monoinfection, with a parasite density of 2000-200,000 parasites per mL of blood; and hemoglobin level у5.0 g/dL. Patients who satisfied the inclusion criteria were randomized; those who were excluded were referred to the dispensary staff for care. Patients were excluded after randomization if slide reevaluation demonstrated a parasite density or species outside of the inclusion criteria or if the subject experienced repeated vomiting of study medication on day 0.
Baseline evaluation, randomization, and treatment allocation. Randomized patients were assigned a study number, interviewed and examined, and referred for treatment allocation by a study nurse not involved in enrollment or assessment of treatment outcomes. Patients were randomly assigned on the basis of a computer-generated code provided by an off-site investigator to oral treatment with the 3 study regimens: (1) artemether-lumefantrine (Coartem; Novartis) administered in tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of 1 tablet (for patients weighing 5-14 kg), 2 tablets (for patients weighing 15-24 kg), 3 tablets (for patients weighing 25-34 kg), or 4 tablets (for patients weighing у35 kg) twice daily for 3 days; (2) dihydroartemisinin-piperaquine (Duocotexcin; Holleypharm) administered in tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a dosage of 6.4 mg of dihydroartemisinin and 51.2 mg of piperaquine per kg of body weight once daily for 3 days; or (3) AQSP, consisting of amodiaquine (Flavoquine; Aventis) administered at a dosage of 10 mg per kg of body weight on days 0 and 1 and 5 mg per kg of body weight on day 2 plus sulfadoxine-pyrimethamine (Fansidar; Roche) administered at a dosage of 25 mg of sulfadoxine and 1.25 mg of pyrimethamine per kg of body weight on day 0. Scored tablets were split and crushed with water for young children. All treatments were directly observed at the clinic or at home for evening doses. The study was not blinded. Patients were observed for 30 min, and doses were readministered if vomiting occurred; those with repeated vomiting on day 0 were excluded from the study prior to enrollment and were referred for treatment with quinine. Paracetamol (10 mg per kg of body weight every 8 h) was provided for treatment of febrile symptoms. Children with hemoglobin levels !10 g/dL were treated according to Integrated Management of Childhood Illness guidelines with ferrous sulfate for 14 days and antihelminthic treatment, if appropriate.
Follow-up procedures and classification of treatment outcomes. Patients were asked to return to the clinic for followup on days 1, 2, 3, 7, 14, 21, 28, 35, and 42 and at any time that they were ill. Subjects who did not return for a scheduled appointment were visited at home. Each visit included completion of a standardized history form, a physical examination, and, except on day 1, a fingerprick for thin and thick blood smear and filter paper storage. Hemoglobin levels were assessed on day 0 and either day 42 or the day of clinical failure. Thick smears were assessed for parasite density and gametocytes. Thin smears to determine speciation were performed for patients who experienced clinical treatment failure after day 3. Patients were followed up for 42 days, and their outcomes were assessed according to World Health Organization (WHO) guidelines as early treatment failure (defined as the presence of danger signs, complicated malaria, or failure to adequately respond to therapy during days 0-3), late clinical failure (defined as the presence of danger signs, complicated malaria, or fever and parasitemia during days 4-42), late parasitological failure (defined as asymptomatic parasitemia without clinical findings during days 7-42), or adequate clinical and parasitological response (defined as the absence of parasitemia throughout follow-up) [20] . Secondary outcomes included the resolution of fever, parasite clearance, change in hemoglobin level, presence of ga-metocytes during follow-up, and the occurrence of adverse events. Patients who experienced treatment failure received quinine (10 mg per kg of body weight orally 3 times per day for 7 days). Patients with evidence of severe malaria or danger signs (i.e., convulsions, lethargy, inability to drink or breastfeed, repeated vomiting, or the inability to stand or sit because of weakness) were referred for treatment with parenteral quinine. Patients were excluded from the study during follow-up for the use of antimalarial drugs outside of the study, serious adverse events requiring a change in treatment, withdrawal of informed consent, or loss to follow-up (defined as not being located within 24 h during days 1-3 or within 48 h during days 4-42).
At each follow-up visit, study clinicians assessed patients for adverse events and graded them according to scales from the WHO and the National Institutes of Health. Adverse events were defined as untoward medical occurrences, following International Conference on Harmonization guidelines, and serious adverse events were defined as experiences resulting in death, life-threatening experiences, inpatient hospitalization, persistent or significant incapacity, or medical or surgical intervention to prevent a serious outcome.
Laboratory procedures. Blood smears were stained with a 2% Giemsa solution for 30 min. Positive screening smear findings were reassessed at a central laboratory. Parasite densities were calculated from thick smears as the number of asexual parasites per 200 leukocytes (or per 500 leukocytes if the parasite density was !10 parasites per 200 leukocytes), assuming a leukocyte count of 8000 leukocytes/mL. Smear findings were considered to be negative when microscopic examination of 100 high-power fields did not reveal parasites. Counts were performed by 2 microscopists; discrepant readings were resolved by a third reader. Gametocytes were recorded as present or absent. Thin blood smears performed on day 0 and on the day of clinical failure were evaluated for parasite species. Hemoglobin levels were measured from finger-prick blood samples using a portable spectrophotometer (HemoCue).
Whenever blood specimens were collected, 4 drops were placed onto filter paper, labeled, air-dried, and stored in sealed plastic bags at ambient temperature. Parasite DNA was subsequently extracted using Chelex (BioRad Laboratories) [21] . For patients experiencing treatment failure after day 6, parasites collected at baseline and at the time of treatment failure were genotyped in a stepwise fashion using msp-2, msp-1, and 4 microsatellites [22] . If, for any of the 6 loci, an allele was not shared between day 0 and the day of recurrence, the infection was classified as a new infection. If at least 1 allele was shared between day 0 and the day of recurrence at all 6 loci, the infection was classified as a recrudescence.
Statistical analysis. We hypothesized that the risk of recurrent parasitemia after 42 days would differ between the group receiving the artemether-lumefantrine regimen and either the group receiving AQSP or the group receiving dihydroartemisinin-piperaquine. On the basis of a prior study [7] that had determined the risk of recurrent parasitemia to be 15% with artemether-lumefantrine therapy and 5% with AQSP therapy, we calculated that 176 patients would be needed in each treatment arm (allowing for a 10% loss to follow-up) to detect a 10% difference in the rate of recurrent parasitemia with a 2-sided type I error of 0.05 and 80% power.
Data were entered using Epi Info software, version 6.04 (Centers for Disease Control and Prevention), and were analyzed using Stata software, version 8.0 (StataCorp). Efficacy and safety data were evaluated using a modified intention-to-treat analysis that included all enrolled patients. Risks of recurrent parasitemia after 28 and 42 days (adjusted and unadjusted by genotyping) were estimated using the Kaplan-Meier product-limit formula. Data were censored for patients who did not complete follow-up and, for adjusted outcomes, for new infections or infections due to agents other than P. falciparum. Comparisons of treatment efficacy were made using risk differences with exact 95% CIs. Categorical variables were compared using x 2 or Fisher's exact test, and continuous variables were compared using the independent samples t test. P values were 2-sided without adjustment for multiple comparisons and were considered to be statistically significant if . P р .05
RESULTS

Enrollment and follow-up.
Of 843 screened patients, 580 fulfilled initial inclusion criteria and were randomized; of these patients, 21 were excluded before enrollment, and 559 were enrolled and treated with study drugs (figure 1). At enrollment there was no significant difference between treatment groups with respect to sex, age, temperature, parasite density, previous use of antimalarial drugs, or mean hemoglobin level (table 1) . Gametocyte carriage was rare. The proportion of patients who did not complete therapy because of repeated vomiting on day 0 (none were excluded for vomiting after day 0), protocol violation, or withdrawal of consent did not differ between the 3 treatment groups (4 of 186 patients for the AQSP group, 3 of 191 patients for the artemether-lumefantrine group, and 8 of 194 patients for the dihydroartemisinin-piperaquine group;
, for all pairwise comparisons). During 42 days of fol-P у .22 low-up, 517 (92.5%) of 559 subjects completed the study. There was no difference in the risk of withdrawal between the treatment arms ( for all comparisons). The most common P 1 .05 reason for study discontinuation was withdrawal of informed consent. jaundice]) and 2 each in the artemether-lumefantrine and dihydroartemisinin-piperaquine groups (all with convulsions). Efficacy outcomes were assigned on the basis of time to early treatment failure or recurrent parasitemia, according to WHO recommendations [20] . Outcomes were assessed after 28 and 42 days and considered with and without genotyping to distinguish recrudescence from new infection. Considering outcomes unadjusted by genotyping, AQSP and dihydroartemisinin-piperaquine regimens were superior to the artemether-lumefantrine regimen at both day 28 and day 42 after the initiation of therapy (table 2). Similar differences were seen with evaluation of outcomes in only those patients !5 years of age. In this group, the 28-day risk of treatment failure was 18.8% for the artemetherlumefantrine regimen, compared with 8.5% for the AQSP regimen and 4.2% for the dihydroartemisinin-piperaquine regimen. Risk difference 95% CIs were 0.7%-20% for the artemetherlumefantrine regimen versus the AQSP regimen and 5.8%-23.4% for the artemether-lumefantrine regimen versus the dihydroartemisinin-piperaquine regimen. The 42-day risk of treatment failure was 30.9% for the artemether-lumefantrine regimen, compared with 17.8% for the AQSP regimen and 12.2% for the dihydroartemisinin-piperaquine regimen. Risk difference 95% CIs were 0.9%-25.4% for the artemether-lumefantrine regimen versus the AQSP regimen and 7.1%-30.2% for the artemetherlumefantrine regimen versus the dihydroartemisinin-piperaquine regimen. Most treatment failures were seen on or after day 21 in the artemether-lumefantrine group, day 28 in the AQSP group, and day 35 in the dihydroartemisinin-piperaquine group (figure 2).
Our genotyping methodology included a step-wise algorithm incorporating 6 markers that was recently validated for the discrimination of outcomes in Bobo-Dioulasso [23] . Genotyping was successful for all of the samples that were tested. Considering only early treatment failures and recrudescences, all tested regimens demonstrated excellent efficacy, with a risk of treatment failure of !5% at day 28 and day 42 for all subjects (table 2) and for those subjects !5 years of age (data not shown). There were no statistically significant differences between groups with respect to the risk of genotype-adjusted treatment failure. Only 1 recrudescence occurred after day 28 (this recrudescence occurred at day 42 in a patient treated with artemether-lumefantrine). Secondary outcomes. Fever clearance was slower among patients who received the artemether-lumefantrine regimen than among patients who received the other 2 regimens; persistence of fever on day 1 was significantly more common in the artemether-lumefantrine group (table 3). More than 80% of patients in all groups cleared fever by day 2. Parasite clearance was slower in the AQSP group than in the other 2 groups. Persistent parasitemia on day 2 was significantly more common in the AQSP group, but by day 3, parasites had cleared in at least 99% of subjects in each treatment group. Gametocytes appeared infrequently (in р5% of subjects) after treatment in all 3 groups. Hemoglobin levels increased after therapy in all groups, but on the last day of follow-up, the mean hemoglobin level was significantly lower in the artemether-lumefantrine group, compared with the other 2 groups.
Adverse events. All tested regimens appeared to be well tolerated. No serious adverse events were observed. Abdominal pain was reported more often in the AQSP and artemetherlumefantrine groups, headache was reported more often in the artemether-lumefantrine group, and pruritis was reported more often in the AQSP group (table 3) .
DISCUSSION
We compared the efficacy against uncomplicated malaria of 3 drug regimens of particular interest in Burkina Faso. AQSP is a combination of 2 older drugs that has shown surprisingly good efficacy in different parts of Africa [9-11, 24, 25] and is advocated under current WHO guidelines for the treatment of malaria where its efficacy has been established and newer ACTs are unavailable [26] . Artemether-lumefantrine is a leading ACT that has shown excellent antimalarial efficacy in Asia [27] [28] [29] and Africa [4] [5] [6] . Dihydroartemisinin-piperaquine is a newer ACT that has not yet been widely studied but which, in available trials, has shown excellent efficacy in Asia [16] [17] [18] and Africa [15] . In Bobo-Dioulasso, all 3 regimens were highly efficacious. For each therapy, early treatment failures or recrudescences after treatment were seen in !5% of patients. However, in Africa, recurrent malaria after therapy is commonly attributable to either recrudescence or new infection, and the most practical means of comparing regimens may be to compare their impacts on recurrent malaria. By this measure, both AQSP and dihydroartemisinin-piperaquine were superior to artemether-lumefantrine, with marked decreases in the risk of recurrent malaria during 6 weeks of follow-up.
The use of ACTs to treat uncomplicated malaria is now strongly advocated [3] . The ACT selected as first-line therapy by the largest number of African countries, artemether-lumefantrine, benefits from coformulation, approval in multiple countries in the developing world and Europe, and demonstrated excellent efficacy and safety [30, 31] . However, disadvantages of artemether-lumefantrine therapy include the need for twice-per-day dosing, irregular bioavailability, and recommendation for ingestion with a fatty meal to improve drug levels. Dihydroartemisinin-piperaquine is a newer coformulated ACT that requires only single daily dosing and lacks dietary concerns. In limited studies, dihydroartemisinin-piperaquine showed outstanding antimalarial efficacy in Asia [16] [17] [18] and Africa [15] . Two recent studies directly compared the antimalarial efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine. In Papua, Indonesia [16] , and in central Uganda [32] , both regimens showed excellent efficacy based on genotype-corrected recrudescence after therapy. However, in both studies, treatment with dihydroartemisinin-piperaquine was followed by significantly fewer new infections during 42 days of follow-up. Thus, as confirmed in our study, dihydroartemisinin-piperaquine appears to offer benefits over artemether-lumefantrine, including simplified dosing and greater posttreatment prophylactic efficacy. Despite the selection of ACTs as first-line antimalarial therapy by most African countries, including Burkina Faso, implementation of changes in malaria therapy have been slow, in part because of the considerable expense and limited availability of new ACTs. The WHO recommends 1 non-ACT regimen, treatment with AQSP, under limited circumstances [26] . AQSP showed surprisingly good antimalarial efficacy in older studies in East Africa [33, 34] , but its efficacy was poor in Tanzania [35] and appears to be decreasing in Uganda [36] , likely as a result of high levels of resistance to both amodiaquine and sulfadoxine-pyrimethamine in East Africa. In contrast, AQSP remains an excellent antimalarial regimen in parts of West Africa, where resistance to both component drugs is uncommon [10, 11] . In a recent comparison in Burkina Faso, AQSP and artemether-lumefantrine both showed outstanding efficacy based on measures of recrudescence, but AQSP demonstrated superior posttreatment prophylaxis against new infections over a month of follow-up [7] . In this study, the superior efficacy of AQSP over artemether-lumefantrine in Bobo-Dioulasso was confirmed. Further, the efficacy of AQSP was not significantly different from that of dihydroartemisinin-piperaquine, although trends favored dihydroartemisinin-piperaquine in all comparisons.
Debate persists regarding the importance of a posttreatment prophylactic effect of an antimalarial drug. Some have argued that recrudescences entail greater clinical risk than new infections after therapy and, thus, that prevention of new infections is relatively unimportant [37] , but clinical data do not support this assertion. In trials in Uganda, clinical presentations and the likelihood of progression to complicated malaria were the same with recrudescent or new malaria episodes [38] . It has also been suggested that, in areas where reinfection is common, posttreatment prophylaxis would have only a minor impact on malarial incidence [39] , but, in fact, with high transmission intensity, the impact of a protective intervention should be large. Indeed, this benefit may be greatest in regions with seasonal transmission, such as Bobo-Dioulasso, where the posttreatment prophylactic effect of a therapy may cover a good portion of the transmission season.
Both amodiaquine and sulfadoxine-pyrimethamine have caused rare but severe toxicities when used for long-term chemoprophylaxis, and artemisinins are embryotoxic and have caused irreversible neurological changes when administered in high doses to laboratory animals. However, a good deal of experience argues against major concerns regarding toxicities of our study regimens when used for short-term antimalarial therapy, although the tolerability of the AQSP regimen has been lower than that of other regimens in some studies [40] . In our study, reports of some adverse events differed between regimens, but all regimens appeared to be well tolerated.
Our results suggest that choices for optimal antimalarial therapy in Africa should be reevaluated. First, in regions where the efficacies of amodiaquine and sulfadoxine-pyrimethamine remain good, as in Burkina Faso, consideration should be given for the use of AQSP for the treatment of uncomplicated malaria, especially when, as a result of the unavailability of ACTs, the alternative is an unacceptable monotherapy. Second, among ACTs, dihydroartemisinin-piperaquine appears to offer particularly promising features, including easy dosing and outstanding antimalarial efficacy, suggesting that this new regimen should be strongly considered for first-line therapy for malaria in Africa.
